Immuron Limited (ASX:IMC)
0.0630
-0.0020 (-3.08%)
Apr 28, 2025, 1:38 PM AEST
Immuron Revenue
Immuron had revenue of 3.99M AUD in the half year ending December 31, 2024, with 584.38% growth. This brings the company's revenue in the last twelve months to 6.54M, up 82.90% year-over-year. In the fiscal year ending June 30, 2024, Immuron had annual revenue of 4.90M with 171.67% growth.
Revenue (ttm)
6.54M
Revenue Growth
+82.90%
P/S Ratio
2.25
Revenue / Employee
934.52K
Employees
7
Market Cap
14.72M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
Jun 30, 2020 | 2.52M | 131.14K | 5.49% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 17.12B |
Ansell | 3.00B |
Mesoblast | 9.16M |
Immuron News
- 17 days ago - Immuron (IMRN) Achieves Record Sales Milestone - GuruFocus
- 17 days ago - Immuron exceeds AUD$5 million in sales in a fiscal year - Seeking Alpha
- 17 days ago - Immuron Travelan® highest sales in history - GlobeNewsWire
- 7 weeks ago - Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - GlobeNewsWire
- 3 months ago - Immuron Travelan® continued strong sales growth - GlobeNewsWire
- 3 months ago - Immuron Announces New Research Collaboration targeting Antimicrobial Resistance - GlobeNewsWire
- 3 months ago - Immuron Announces Travelan® Clinical Trial Update - GlobeNewsWire
- 5 months ago - Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th - GlobeNewsWire